The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Most sources were saying a vaccine would be available by the end of last year.
Very few people in the UK have been vaccinated according the clinical trial protocol
Virus mutates very fast
Lots of UK population will refuse to get vaccinated
Lots of people will mount insufficient immune response to vaccine
Lots of world population will never get vaccinated
It is clinically necessary to distinguish covid from other similarly presenting respiratory conditions
PCR based testing in medicine is expanding rapidly
Vaccination of entire populations is costly and logistically challenging
Had a bit of experience of working with Deloitte consultants, you wouldn't want any of them advising you on healthcare or any scientific matters.
Someone in the government awarding these contracts is corrupt or stupid and giving contracts to firms like Deloitte and Innova.
Novacyt have great products, are leading the way and should have their government contract extended, but the government seem erratic in their decision making and not necessarily guided by the facts
The problem is they all respond to each other and like it was a couple of days ago the board was overrun by them. Starving them of oxygen isn't necessarily a successful strategy.
Baiting CS is just a bit of fun, he's a green box to me but he needs the response from people for the sake of his own well being, why else would he come here? I reply purely to help his mental health
Moonpig is a very easy business to understand.
Novacyt isn't and it can be difficult for investors to appraise their technology and its potential. Most investors probably don't know what a SNP really is.
It is dangerous investing without research. AVCT is a prime example of this. At the start of the pandemic there was plenty of research demonstrating that they were orders of magnitude away from the levels required to detect covid and that at best would take them a long time to resolve this. Yet some people, still invested back then... but all ended well as CS help fund Al's new house
The last week has certainly seen a few of the day traders, earning their £50 a day come out of the woodwork.
I do appreciate their generosity though in offering us tips on which news shares to transfer profits to.
Their posts are predictable and boring and it's not worth being on here until they've gone.
That is management accounts which are used for internal reporting, they will still be checked over.
This is year end financial account reporting that takes a while. If the finance team make a material misstatement to the IS they will be in the...
Strength of antibodies don't decline.
Half life of antibodies is not overly long though.
It is the longevity, number and responsiveness of the cells that produce the antibodies which matter - this varies.
In all likelihood an immune response will be mounted if previously exposed within a reasonable timeframe but viral mutations may hinder the efficacy of an immune response.
There are many unknowns at present. For instance, it was only a few months ago that our friend Seadoc was predicting that no vaccine would ever be developed. If I remember correctly he had some other prescient insights.
There are much better trials being conducted which are looking at multiple interferon/cytokine/steroid combinations but you would know this as will the informed posters on SNG.
Many of these agents are cheaper and have longer safety data for use in patients.
Trying to stop the uninformed ramping of another share on this board
Hard - there are home steroid which you would know if you were clued up. Patients use these all the time for multiple conditions. Do you want to walk you through all the steroid routes?
What proof do you have they are in contact with the CEO?
Do you think just placebo is a suitable control when there are broad spectrum immune modulators that can be used in all settings in all stages in disease?
Units is more likely but it says kits which makes me wary of how much stock to put in the tweet either way.
Is dexmethasone better than interferon, could well be and effectively free. Antibody treatments are far better than a broad spectrum immunomodulator.
I know some people say there are informed SNG posters but not seen any yet. I hope it doesn't continue down the AVCT cross ramping and anti informed discussion route
1500 - a lot less than Novacyt then? Everything is relative. So yes, compared to Novacyt, which this is board is for, I am advising against them over the previous year. The question is the future, and what timeframe in the future. I think there are better investments to be had.
Look at the confidence intervals in the phase 2 trial. What was it compared to? Should be more arms in the trial comparing to more treatments. Always should be less redtape
Their biomarkers and relationships are their strengths.
I had some reservations previously but they have released announcements that they are looking at more markers, and different types. They are also looking at treating the high and low risk groups with relationships with companies that manage lifestyle and others that are drug developers. This is big step forward as they are developing clear plans for the different risk stratified groups
Their algorithms are not advanced compared to others such as DeepMind. I wouldn't invest here if you are looking for groundbreaking algorithms that can be transferred to other fields
There are uninformed rampers here as everywhere and best ignoring them.
SNG are ramped hard across the boards.
Their upcoming phase 3 is not well designed and there. Most likely a broad immune system modulator that the trial won't distinguish
Much better biotech plays out there to be found with a bit of research.
Wilson - Good luck for the surgery, not that you need it, you'll do great. You do need luck for a good ward/bed where you can actually get some sleep and no amount of luck will get you good food unfortunately!
HarsChris - good post but one point. Avacta don't actually have any groundbreaking technology.
Other companies are doing alternatives to antibodies and their cancer drugs are not innovative.
The differentiator in most companies is the execution as there really aren't many truly innovative ideas in most companies.
If you really want a disruptor, a true innovation, then it is DeepMind's protein folding advancements. That is groundbreaking and has the potential to revolutionise medicine. That advancement cannot be overstated.
Would be good to see another domestic company do well but Avacta have been badly mismanaged.
Following their article in the Guardian I think, back in the summer, they got a major boost to their SP but there was no substance to that article and I always wondered what the motivation there was to publish it. I think most people can work out what the motivation was.
Miagi - I do work with that tech but never mind. Good dodge on answering anything technical. I take it you are not from a scientific, medical or even financial background.
Your unsubstantiated comments were in regards to the price dropping and you trying this on other boards.
Similar comments on a gold miner. How you doing on that one?